Sign In
Search Icon
Menu Icon

Reporting All USG Procured Therapeutics in HPOP

As noted in the August 10, 2022, guidance update for the reporting of COVID-19 hospital data, reporting inventory of sotrovimab, bamlanivimab/etesevimab (bam/ete), and casirivimab/imdevimab (REGEN-COV) were moved from the COVID‑19 hospital data collection (currently reported through TeleTracking or state reporting systems) to the Health Partner Ordering Portal (HPOP) as of November 2, 2022, consolidating reporting for all products into one system.

Reporting of all USG supply remains mandatory until all doses delivered are accounted for as administered, wasted (unusable due to damage or expiration), or transferred to another facility.

Health Partner Ordering Portal (HPOP)

HPOP is an ordering portal for allocating and/or requesting U.S. government (USG) procured medical counter measures and other products, including COVID-19 therapeutic products, and is used to order and report utilization of those products.

Required reporting cadence in HPOP

Reporting cadence for legacy mAbs will be due on the last day of the month.  The active therapeutics must be reported on the 15th and the last day of each month. HPOP accounts for sites that have not reported in 90 days will be deactivated. Contact the helpdesk to reactivate.

User guides for HPOP

Written user guides for partners and sites are posted in HPOP in the Partner and Site Portals respectively and were distributed to partners.

Help Desk and Support

The HPOP Helpdesk should be the first stop for all issues related to HPOP COVID‑19 Therapeutics:

For general utilization reporting questions contact